SRR934790
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 10.873850197109066
- age_years
- 57
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.488
- G2M_CHECKPOINT+0.437
- MYC_TARGETS_V1+0.309
- MYC_TARGETS_V2+0.256
- SPERMATOGENESIS+0.225
- DNA_REPAIR+0.198
- PANCREAS_BETA_CELLS+0.118
- CHOLESTEROL_HOMEOSTASIS-0.051
- KRAS_SIGNALING_DN-0.069
- ALLOGRAFT_REJECTION-0.083
Top 10 suppressed
- HYPOXIA-0.480
- UV_RESPONSE_DN-0.460
- TNFA_SIGNALING_VIA_NFKB-0.455
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.426
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.425
- MYOGENESIS-0.399
- TGF_BETA_SIGNALING-0.385
- IL2_STAT5_SIGNALING-0.381
- ADIPOGENESIS-0.367
- APOPTOSIS-0.367
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02728 | — | cohortMD1 | 0.915 |
| 2 | BS_QT3NZ2YZ | Embryonal tumors | — | 0.908 |
| 3 | BS_1BWP5MCT | medulloblastoma | — | 0.904 |
| 4 | TCGA-85-A510-01A-11R-A26W-07 | — | cohortA3 | 0.900 |
| 5 | BS_VVFBW0YH | medulloblastoma | — | 0.898 |
| 6 | BS_3NWQXPQV | medulloblastoma | — | 0.897 |
| 7 | SRR934905 | — | — | 0.897 |
| 8 | SRR8526719 | — | cohortMD1 | 0.895 |
| 9 | SRR1313143 | — | E | 0.895 |
| 10 | BS_9PB3XH5D | medulloblastoma | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.488 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.437 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.309 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.256 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.225 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.198 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.118 | Cobimetinib | — uncovered |